Sanofi Q1 profit slips on generic competition, forex effects
Sanofi is narrowing development of one of its 5 billion euro ($5.4 billion), “pipeline-in-a-product” assets. The French drugmaker axed Sjögren’s syndrome from the list of targeted indications for frexalimab after seeing phase 2 efficacy data—and reported a phase 3 flop for one of its tarnished former top prospects.
FDA Approves Novartis` Lutathera for Children With Neuroendocrine Cancers
Sanofi plans to file for approval of a “multi-indication blockbuster” that it predicts could contribute to more than 10 billion euros of launch sales.
Australia’s industry body for biotechnology, AusBiotech, has announced ex-Sanofi leader Rebekah Cassidy as its incoming Chief Executive Officer.
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential...
Sanofi will pay $100 million—or approximately $25,000 each—to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (ranitidine) can cause cancer. Bloomberg reported the figure, citing sources familiar with the deal.
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices.
Sanofi to overhaul US operations of vaccines, cut jobs